Sunshine Biopharma Inc. warrant financials
$0.0540+74.19%
Close Sep 18, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M | $8.1M | $8.6M | $9.4M | $9.4M | $8.9M | $9.6M | $8.4M | $9.3M | $7.5M | $7.7M | $6.0M |
| Gross profit | $2.4M | $2.2M | $3.0M | $3.1M | $3.4M | $2.7M | $3.1M | $2.9M | $2.4M | $2.4M | $2.6M | $2.0M |
| Gross margin | 26.2% | 27.0% | 35.3% | 32.6% | 36.4% | 30.7% | 32.2% | 34.0% | 25.3% | 31.2% | 33.4% | 33.4% |
| Operating income | -$1.6M | -$1.4M | -$1.8M | -$1.1M | -$2.1M | -$1.3M | -$2.0M | -$1.1M | -$1.3M | -$1.4M | -$1.2M | -$779.5K |
| Net income | -$1.6M | -$1.2M | -$2.1M | -$883.8K | -$1.8M | -$1.2M | -$2.2M | -$1.2M | -$494.3K | -$1.3M | -$1.3M | -$651.5K |
| Net margin | −16.9% | −15.4% | −25.0% | −9.4% | −18.8% | −13.3% | −22.5% | −14.2% | −5.3% | −17.0% | −16.3% | −10.9% |
| Diluted EPS | $-1.15 | $-2.50 | $-2.40 | $-1.90 | $-3.94 | $-4.40 | $-25.44 | $-9.40 | $-99.40 | $-20.00 | $-257.52 | $-507.20 |
| EBITDA | -$1.2M | -$1.2M | -$1.5M | -$242.8K | -$855.4K | -$1.2M | -$1.7M | -$923.4K | -$994.0K | -$1.1M | -$1.1M | -$742.3K |
| Operating cash flow | -$918.0K | -$2.1M | -$1.6M | -$727.8K | -$1.3M | -$1.7M | -$3.4M | -$1.4M | -$4.6M | -$3.2M | -$2.6M | -$457.3K |
| Free cash flow | -$925.0K | -$2.1M | -$1.6M | -$735.8K | -$1.4M | -$1.7M | -$3.5M | -$1.9M | -$5.6M | -$3.2M | -$2.9M | -$466.9K |
| Diluted shares | 1.4M | 0.5M | 0.9M | 0.5M | 0.4M | 0.3M | 0.1M | 0.1M | 0.0M | 0.1M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.7M | $6.9M | $9.1M | $9.3M | $10.3M | $8.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $33.6M | $27.9M | $30.1M | $31.5M | $32.0M | $29.2M |
| Total liabilities | $6.1M | $6.4M | $7.0M | $7.3M | $6.3M | $6.5M |
| Shareholders' equity | $27.5M | $21.5M | $23.0M | $24.2M | $25.7M | $22.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology